Taysha Gene Therapies, Inc. (TSHA) NASDAQ

5.91

+0.2(+3.50%)

Updated at December 24 01:00PM

Currency In USD

Valuation

Market Cap376.84M
Enterprise Value301.36M
P/E Ratio-20.9
PEG Ratio-7.1
Price/Sales Ratio213.42
Price/Book Ratio9.53
Enterprise/Revenue168.91
Enterprise/EBITDA-10.63

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterSeptember 30, 2025

Profitability

Profit Margin-15.84
Operating Margin-16.19

Management Effectiveness

Return On Assets-0.32
Return On Equity-0.67

Income Statement

Revenue8.33M
Revenue/Share0.02
Gross Profit8.33M
EBITDA-87.95M
Net Income-89.3M
Diluted EPS-0.36

Balance Sheet

Total Cash297.34M
Total Cash/Share0.84
Total Debt69.08M
Total Debt/Equity0.08
Current Ratio10.48
Book Value Per Share0.62

Price History

52-Week Change219.46
52-Week High6.02
52-Week Low1.05
Moving Average 50 Days4.81
Moving Average 200 Days3.12

Statistics

Average Volume6.27M
Shares Outstanding300.48M
% Held by Institutions88.79

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A